There is a new potential Reglan lawsuit in the pipeline. The ingredient in the original topical form has caused liver cancer in many patients, including one-third of those who have used it to treat their Crohn’s Disease (CRD) or ulcerative colitis. The synthetic form shows even greater promise for treating other cancers and inflammatory bowel diseases (IBD). Here is more on the topic.
Crohn’s disease is a chronic disorder of the digestive tract that causes inflammation and is sometimes accompanied by severe pain.
Ulcerative colitis is an inflammatory bowel disease that also causes painful rectal bleeding. It is very painful and causes ulcers in the colon, which is why so many people are interested in treating it. In fact, many believe that ulcerative colitis is an addiction that must be treated, or it will only get worse over time.
Currently, there are clinical trials underway for a new ulcerative colitis treatment, Reglan.
This treatment is said to “miraculously” cure ulcerative colitis, Crohn’s disease or any other form of cancer, as long as the drug is taken over a long period of time. But what about Reglan’s potential for causing cancer, since it is still being studied in this very active and exciting clinical trial? Is this new drug safe, especially for cancer patients?
Currently, the answer seems to be “yes”, but you should read the study thoroughly. Many details about the Reglan lawsuit have been reported by the media, but there have also been some wild claims coming from some Reglan manufacturers. For instance, one manufacturer claimed that it is a “cure” for cancer. Others have claimed that the drug holds the potential for treating “all” of the following: ulcerative colitis, Crohn’s disease, cancers of the colon, bladder, leukemia, lymphoma, skin disease, liver disease, pancreatic disease, respiratory disease, and possibly even more. Even some doctors have commented on the potential for treating “all” of these conditions.
If true, this would certainly mean that Reglan can cure all ulcerative colitis, Crohn’s disease, cancers of the colon, bladder, leukemia, skin disease, liver disease, and possibly more.
Some researchers are very worried about the potential for this outcome. One of them is Professor Paul Barr, from the University of Glasgow. He recently published his findings in an English journal, saying that “the results are alarming”. As if that was not enough, he went on to state that “The combination of this drug with a significant change in diet, which has yet to be tested in clinical trials, makes it impossible to say how much the drug will help, or whether it will improve any of the conditions we have mentioned”.
It should be noted that in regards to clinical trials, some research participants may not gain benefit from the drugs and this does not necessarily mean that the drugs should not be used.
In fact, many patients are able to control their cancers with standard treatments that do not require the use of medications. But, this still does not change the fact that the clinical trials must be conducted and monitored, so the results of the studies can be significant. If this new development holds true, then thousands of people may actually be able to slow or stop cancer, even with early stage cancer.
Now, the question becomes whether this type of lawsuit is meritorious and appropriate.
It will be interesting to see what the courts have to say. Right now, there is no law in the country that requires anyone to prove that they have a diagnosed condition in order to file a lawsuit. Although, there are two cases currently being tried in the courts involving Reglan and ulcerative colitis, and there is a pending fourth trial in a Florida court.
It will be interesting to see whether either the plaintiff or the defendant (the pharmaceutical company) can successfully use this type of lawsuit in an attempt to gain relief from their condition. Hopefully, the answer will be “yes.” Either way, it appears that there is hope for those with ulcerative colitis and other forms of diseases, as there have been a number of successful lawsuits in recent years. Whether or not these lawsuits hold merit remains to be seen, but at least one lawsuit has already been launched.